U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Kiara Fairman
  1. Science & Research (NCTR)

Kiara Fairman M.S., Pharm.D

Staff Fellow — Division of Biochemical Toxicology

Photo of Kiara Fairman

Kiara Fairman, M.S., Pharm.D.
(870) 543-7121
NCTRResearch@fda.hhs.gov

Back to NCTR Principal Investigator page  

About  |  Publications  |  Lab Members

Background

Dr. Fairman is a staff fellow at FDA’s National Center for Toxicological Research (NCTR). She previously served as an Oak Ridge Institute for Science and Education (ORISE) postdoctoral fellow at NCTR from 2019–2021, where she worked on physiologically-based pharmacokinetic modeling tools for regulatory decision making in pregnancy and other life stages. She received a Doctor of Pharmacy degree from the University of North Texas System College of Pharmacy in Fort Worth, Texas. She holds a Certificate in Regulatory Science from the University of Arkansas for Medical Sciences; a Master of Science degree in biological sciences—chemistry track from the University of Texas Southwestern Medical Center in Dallas, Texas; and a bachelor’s degree in chemistry from Alabama State University. Dr. Fairman has attended and presented at various conferences and annual meetings in the areas of toxicology, clinical pharmacology, pharmacy, and chemistry.

Dr. Fairman has received honors and awards including:

  • Biological Modelling Specialty Section – Society of Toxicology (SOT) Best Abstract Award (2021)
  • Computational Toxicology Specialty Section (SOT) Postdoc Award (2021)
  • 2nd Place, South Central Chapter SOT Non-Student/Non-Faculty Platform Presentations (2020)
  • American Chemical Society Division of Chemical Toxicology Outstanding Poster Award (2020)

 

Research Interests

Dr. Fairman’s research interests include making physiologically based pharmacokinetic (PBPK) modeling widely available in clinical practice, making it a tool for individualized bedside medicine. Her focus in the subject of PBPK modeling includes unique and underrepresented patient population areas such as pregnancy, ethnicity, and disease state modeling. Dr. Fairman is also interested in medicinal chemistry, natural products, and clinical pharmacology research. She is also working on incorporating new advancements—such as artificial intelligence (AI) and machine learning—into PBPK modeling. Her expertise lies in PBPK modeling, pharmacy, and chemistry. Her current research goals include learning AI and collaborating with experts to incorporate AI into a PBPK model for automation and model confidence building as a tool for regulatory use.

 

Professional Societies/National and International Groups

American Association of Pharmaceutical Scientists
Member
2020 – Present

American College of Clinical Pharmacology
Member
2017 – Present

American Society of Health-System Pharmacists
Member
2016 – 2020, 2023

FDA Fellows Association
Member
2019 – Present
Social Media Representative Co-Chair
2019 – 2020

Jefferson Laboratories Fellows Advisory Committee
Member
2019 – Present
Social Committee Member
2019 – 2020

Society of Toxicology
Member
2019 – Present
Risk Assessment Specialty Section Postdoctoral Representative
2019 – 2021
Postdoctoral Association Treasurer
2020 – 2021

 

Selected Publications

Prediction of Physicochemical and Pharmacokinetic Properties of Botanical Constituents by Computational Models.
Liu Y., Lawless M., Li M., Fairman K., Embry M.R., and Mitchell C.A.
Journal of Applied Toxicology. 2024, doi: 10.1002/jat.4617. Epub ahead of print.

An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science. 
Fairman K., Choi M.K., Gonnabathula P., Lumen A., Worth A., Paini A., Li M., and Kabadi S. 
Toxics. 2023, 11(2):126. doi: 10.3390/toxics11020126.

Physiologically Based Pharmacokinetic (PBPK) Modeling of RNAi Therapeutics: Opportunities and Challenges.
Fairman K., Li M., Ning B., and Lumen A.
Biochem Pharmacol. 2021, 189:114468. doi: 10.1016/j.bcp.2021.114468. [Epub Feb 10, 2021].

Physiologically Based Pharmacokinetic Modeling: A Promising Tool for Translational Research and Regulatory Toxicology. 
Fairman K., Li M., Kabadi S., and Lumen A.
Current Opinion in Toxicology. 2020, 23–24, 17-22, https://doi.org/10.1016/j.cotox.2020.03.001.

 

Lab Members

Contact information for all lab members:
(870) 543-7121
NCTRResearch@fda.hhs.gov

Miguel Romanello Giroud Joaquim, M.S.
ORISE Fellow

Contact Information
Kiara Fairman
(870) 543-7121
Expertise
Expertise
Approach
Domain
Technology & Discipline
Toxicology
Back to Top